Peter Lamb Net Worth

The estimated Net Worth of Peter Lamb is at least $12.3 Million dollars as of 15 December 2022. Peter Lamb owns over 20,000 units of Exelixis Inc stock worth over $11,476,412 and over the last 18 years he sold EXEL stock worth over $0. In addition, he makes $784,706 as Executive Vice President - Scientific Strategy and Chief Scientific Officer at Exelixis Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Peter Lamb EXEL stock SEC Form 4 insiders trading

Peter has made over 41 trades of the Exelixis Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of EXEL stock worth $84,000 on 15 December 2022.

The largest trade he's ever made was exercising 300,876 units of Exelixis Inc stock on 12 October 2015 worth over $1,693,932. On average, Peter trades about 24,996 units every 55 days since 2007. As of 15 December 2022 he still owns at least 430,958 units of Exelixis Inc stock.

You can see the complete history of Peter Lamb stock trades at the bottom of the page.

Peter Lamb biography

Dr. Peter Lamb Ph.D. serves as Executive Vice President - Scientific Strategy, Chief Scientific Officer of the Company. Peter Lamb, Ph.D., has served as Executive Vice President, Scientific Strategy and Chief Scientific Officer since February 2016. Previously, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. He has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. He has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.

What is the salary of Peter Lamb?

As the Executive Vice President - Scientific Strategy and Chief Scientific Officer of Exelixis Inc, the total compensation of Peter Lamb at Exelixis Inc is $784,706. There are 8 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.

How old is Peter Lamb?

Peter Lamb is 59, he's been the Executive Vice President - Scientific Strategy and Chief Scientific Officer of Exelixis Inc since 2016. There are 12 older and 8 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.

What's Peter Lamb's mailing address?

Peter's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.

Insiders trading at Exelixis Inc

Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.

What does Exelixis Inc do?

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.

Complete history of Peter Lamb stock trades at Exelixis Inc

Exelixis Inc executives and stock owners

Exelixis Inc executives and other stock owners filed with the SEC include:

• Dr. Michael M. Morrissey,
  CEO, Pres & Director
• Michael Morrissey,
  President, Chief Executive Officer, Director
• Gisela Schwab,
  President - Product Development and Medical Affairs, Chief Medical Officer
• Christopher J. Senner,
  Exec. VP & CFO
• Christopher Senner,
  Chief Financial Officer, Executive Vice President
• Jeffrey J. Hessekiel,
  Exec. VP, Gen. Counsel & Sec.
• Jeffrey Hessekiel,
  Executive Vice President, General Counsel
• Patrick J. Haley M.B.A., MBA,
  Exec. VP of Commercial
• Peter Lamb,
  Executive Vice President - Scientific Strategy, Chief Scientific Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board, Co-Founder
• Charles Cohen,
  Independent Director
• Jack Wyszomierski,
  Independent Director
• George Poste,
  Independent Director
• Vincent Marchesi,
  Independent Director
• Julie Smith,
  Independent Director
• Alan Garber,
  Independent Director
• Maria Freire,
  Independent Director
• Carl Feldbaum,
  Independent Director
• Lance Willsey,
  Independent Director
• Dr. Stelios Papadopoulos Ph.D.,
  Co-Founder & Independent Chairman
• Patrick Haley,
  Executive Vice President - Commercial
• Laura Dillard,
  Exec. VP of HR
• Gregg Bernier,
  VP of Marketing
• Susan T. Hubbard,
  Exec. VP of Public Affairs & Investor Relations
• Dr. Peter Lamb,
  Exec. VP of Scientific Strategy & Chief Scientific Officer
• Dr. Dana T. Aftab,
  Exec. VP of Bus. Operations
• George A Scangos,
  Director
• Dana Aftab,
  CSO/EVP Disc & Trans Research
• Mary C Beckerle,
  Director
• David Edward Caligan Partne...,
  
• Sue Gail Eckhardt,
  Director
• Bob Oliver,
  Director
• Tomas J. Heyman,
  Director
• Jacqueline Wright,
  Director
• Pamela A Simonton,
  VP, Corp Tech Development
• Frank Karbe,
  Senior VP & CFO
• Deborah Burke,
  SVP & Chief Financial Officer
• Jeffrey Latts,
  Sr VP, Chief Medical Officer
• Peter Stalder,
  Director
• Jason S Fisherman,
  Director
• Kristine M Ball,
  Controller & Interim CFO
• Frank Mccormick,
  Director
• Steven P James,
  Sr VP, Commercial Ops
• Jane M Green,
  VP, Corp Communications
• Glen Y Sato,
  CFO Sec and General Counsel
• Jean Francois Formela,
  Director
• Lupe M Rivera,
  VP, HUMAN RESOURCES
• Frances K Heller,
  EVP, Business Development
• Ian D Malcolm,
  VP, STRATEGIC MARKETING
• Christoph Pereira,
  VP, Legal Affairs & Secretary
• J. Scott Garland,
  EVP & Chief Commerical Officer
• Gregory Plowman,
  Sr VP, Research
• Geoffrey M Duyk,
  Pres R&D & Chief Sc Off
• Vicki L Goodman,
  EVP, Prod Dev & Med Aff &CMO
• Amy C. Peterson,
  EVP Prod Dev & Med Aff & CMO